Pharmacotherapy for chronic obstructive pulmonary disease
In-Ae KIM; Yong-Bum PARK; Kwang-Ha YOO.
Journal of the Korean Medical Association
; : 545-551, 2018.
ArtÃculo en Ko | WPRIM | ID: wpr-916165
Documentos relacionados
The effect and associated mechanism of action of phosphodiesterase 4 (PDE4) inhibitor on CD4+ lymphocyte proliferation.
Nonantibiotic Pharmacological Treatment of Severe Chronic Obstructive Pulmonary Disease Exacerbations.
Phosphodiesterase-4 inhibitor therapy for lung diseases.
Pharmacotherapy for chronic obstructive pulmonary disease
Inflammation in chronic obstructive pulmonary disease: implications for new treatment strategies.
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
Chronic Obstructive Pulmonary Disease: Diagnosis and Management.
Switching from long-acting beta-agonist and inhaled corticosteroid to long-acting beta-agonist and long-acting muscarinic antagonist for chronic obstructive pulmonary disease: a case report of inhaled corticosteroid withdrawal.
Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes.
Future treatment of chronic obstructive pulmonary disease.